Sector News

J&J completes acquisition of Alios Biopharma

November 12, 2014
Life sciences
Johnson & Johnson (J&J) announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.
 
With this acquisition complete, Alios BioPharma will now become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The acquisition includes Alios BioPharma’s portfolio of potential therapeutics for viral infections with the promising compound AL-8176, an orally administered antiviral therapy currently in phase 2 studies for the treatment of infants with respiratory syncytial virus (RSV).  RSV is the last of the major paediatric diseases that currently has no effective therapy.  The acquisition also includes two early-stage compounds for hepatitis C (HCV) that could potentially augment Janssen’s existing HCV portfolio.
 
“The acquisition of Alios BioPharma further reflects our commitment to bringing together the best science from around the globe to address significant unmet need.   Together we will further strengthen Janssen’s infectious diseases pipeline to address the needs of patients and families affected by some of the world’s most devastating diseases,” said Paul Stoffels, M.D., chief scientific officer of Johnson & Johnson and Worldwide chairman, pharmaceuticals.
 
Source: pharmabiz

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach